MedTrace Logo

Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics

NCT04678089 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2022-04-28

No results posted yet for this study

Summary

With the emergence of new drugs, the short-term survival rate of multiple myeloma has been significantly increased. However, in clinical treatment, doctors found that different patients may present different clinical efficacy and adverse reactions when using standard treatment. Some studies have shown that gene and metabolic differences in patients with multiple myeloma may be an important factor affecting clinical efficacy.

In this project, peripheral blood samples and bone marrow from patients with multiple myeloma will be studied by using the methods of genomics, proteomics, metabonomics and transcriptomics. It is expected to find biomarkers and genes related to clinical efficacy, adverse reactions, and blood concentration of bortezomib in peripheral blood samples. If the sample size is large enough, the project team expects to establish a prediction model for the efficacy and safety of bortezomib containing regimen for multiple myeloma patients through the above studies. Investigators hope that the evaluation system can provide a reference for clinical formulation of appropriate drug delivery scheme.

Conditions

Interventions

DRUG

Bortezomib

Objective To observe the safety and efficacy of bortezomib related biomarkers. Including genes, metabolites, etc

Sponsors & Collaborators

  • Beijing Chao Yang Hospital

    lead OTHER

Principal Investigators

  • Lihong Liu, Doctor · Beijing Chao Yang Hospital

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-16
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04678089 on ClinicalTrials.gov